One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens) - Related Studies

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

This study has been completed.

Study NCT00246467. Last updated on September 12, 2008. Information provided by PharmAthene UK Limited

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Plague

2	More general conditions related to this trial
		Bacterial Infections
		Enterobacteriaceae Infections
		Gram-Negative Bacterial Infections
		Yersinia Infections

3	Interventions listed in this trial
		Alhydrogel
		rF1 and rV protein antigens

4	Additional drug interventions recognized in this trial
		Aluminum Hydroxide

5	More general drug interventions related to this trial
		Adjuvants, Immunologic
		Antacids
		Immunologic Factors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs

6	Sponsors listed in this trial
		PharmAthene UK Limited
		National Institute of Allergy and Infectious Diseases (NIAID)